Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus–Exposed Individuals
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad412 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Davide Moschese und 13 weiteren Autor:innen. Beteiligte Einrichtung: I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Mpox, Monkeypox, Virus Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor—We read with interest the article by Ogale et al [1] in which they report on the presence of mpox virus exposure using direct (polymerase chain reaction [PCR]) and serological (anti-orthopox virus immunoglobulin G [IgG] and IgM) methods in patients who present for their first JYNNEOS vaccine administration without characteristic lesions or rash. The authors found that of 324 patients without a positive PCR specimen, 47 (15%) presented with a positive anti-orthopox virus IgG titer, 6 also with a positive IgM titer. Two additional patients presented with IgM positivity only. Considering that 36 of these patients were aged >50 years or had a known history of smallpox vaccination, we could speculate that in this subsample, 13 of 324 patients (4%) could have been exposed to the mpox virus. At our center (Infectious Diseases Department, Luigi Sacco Hospital, Milan, Italy), we started our mpox vaccine campaign during the same period reported by Ogale et al with a hybrid model (JYNNEOS vaccine, the first 0.5-mL subcutaneous dose [SC] followed by a 0.1-mL intradermal dose [ID] 4 weeks apart) with blood sampling performed at baseline (first dose, SC: T0), week 4 (second dose, ID: T1), and week 12 (T2). Virus-neutralizing antibody titers were estimated using the plaque reduction neutralization test (PRNT) against the mpox virus. Thus, we were able to assess the proportion of patients who presented with a neutralization titer for mpox at the time of the first vaccine and assess the hybrid vaccination-induced humoral immunity over time. Seventy-seven male patients had an available T0 sample, 6 of whom (7.8%) showed a positive PRNT (range, 1:10–1:80), age range of 32–49 years, and none reported previous smallpox vaccination or mpox-related signs or symptoms, suggesting a possible previous unrecognized pauci/asymptomatic mpox infection (mpox-exposed; Table 1) [2]. After excluding 5 patients lost to follow-up, the remaining 66 patients (mpox-unexposed) underwent complete sample collection. At T1, the PNRT for mpox-exposed patients ranged from 1:20 to 1:320 (Supplementary Table 1), and for the mpox-unexposed patients, the median PRNT was 1:20 (1:20–1:40). At T2, PNRT for mpox-exposed patients ranged from 1:40 to 1:320 (4 of 6 patients >1:160), and for the mpox-unexposed patients, the median PRNT was 1:40 (1:20–1:80). When compared with T1, no mpox-exposed patients showed a decline in PRNT at T2, whereas 17 (25.8%) unexposed patients showed a decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
- Laboratory of Clinical Microbiology, Luigi Sacco Hospital, Milan, Italy.
- III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
- Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.
- Infectious Disease Unit II, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milano, Italy.
- Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy.
ORCID-Profile: Andrea Giacomelli
Zitieren
APA
Moschese, D., Bianchi, M., Cossu, M. V., Salari, F., Giacomelli, A., Rizzo, A., Lazzarin, S., Sabaini, F., Nozza, S., Mileto, D., Gori, A., Antinori, S., Gismondo, M. R., & Rizzardini, G. (2023). Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus–Exposed Individuals. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad412
Vancouver
Moschese D, Bianchi M, Cossu MV, Salari F, Giacomelli A, Rizzo A, et al. Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus–Exposed Individuals. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad412
BibTeX
@article{Moschese2023,
author = {Moschese, Davide and Bianchi, Micol and Cossu, Maria Vittoria and Salari, Federica and Giacomelli, Andrea and Rizzo, Alberto and Lazzarin, Samuel and Sabaini, Federico and Nozza, Silvia and Mileto, Davide and Gori, Andrea and Antinori, Spinello and Gismondo, Maria Rita and Rizzardini, Giuliano},
title = {Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus–Exposed Individuals},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad412}
}
EUVIMED